Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 12/20 | 0.62 |
| ▸ | CNR2 | P34972 | 9/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | PLK1 | P53350 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24437217 | 0.94 | CNR1 (0.66) | CNR1CNR2NPSR1PLK1 | |
| SCHEMBL3105128 | 0.93 | CNR1 (0.72) | CNR1CNR2NPSR1PLK1 | |
| SCHEMBL30421188 | 0.90 | LMNA (0.64) | CNR1CNR2LMNA | |
| SCHEMBL9028840 | 0.90 | LMNA (0.64) | CNR1CNR2LMNA | |
| SCHEMBL7291403 | 0.88 | CNR1 (0.60) | CNR1CNR2NPSR1KMT2A | |
| SCHEMBL29601308 | 0.87 | CNR1 (0.59) | CNR1CNR2NPSR1PLK1LMNA | |
| SCHEMBL24437322 | 0.87 | CNR1 (0.59) | CNR1CNR2NPSR1PLK1LMNA | |
| SCHEMBL9344560 | 0.87 | CNR1 (0.62) | CNR1CNR2PLK1KMT2A | |
| SCHEMBL7388847 | 0.84 | CNR1 (0.56) | CNR1CNR2NPSR1 | |
| SCHEMBL7331887 | 0.83 | HRH2 (0.54) | CNR1CNR2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220153735-A1 | Orai Channel Inhibitors | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 2022-05-19 | — | — | US | disclosed |
| US-4940703-A | Spirocyclic compounds incorporating five-membered rings with two heteroatoms for treating psychotic disorders, etc. | MERCK SHARP & DOHME LIMITED (GB) | 1990-07-10 | — | — | US | disclosed |
| EP-0337547-A1 | Spirocyclic compounds incorporating five-membered rings with two heteroatoms | MERCK SHARP & DOHME LTD. (GB) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459938-B2 | ORAI channel inhibitors | ORAI1, CACNA1E, ORAI3 | CNR1 86/4885CNR2 209/4885NPSR1 875/4885 |
| US-20220153735-A1 | Orai Channel Inhibitors | ORAI2, ORAI1, ORAI3 | CNR1 940/4885CNR2 745/4885NPSR1 1530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.